The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd's carrying and forwarding (C&F) warehouse in Pune. This action follows alleged violations related to packaging, storage, documentation, and recall of Reactin Plus Tablets, a Schedule H drug. The FDA cited issues like misbranding, inadequate storage conditions, and deficiencies in record-keeping, reiterating its commitment to ensuring medicine safety and compliance.
The Bombay High Court severely criticised the Maharashtra FDA for its "undue haste" and "high-handed" actions, forcing the regulator to withdraw orders against Cipla Pharma and five restaurants at the Mumbai Cricket Association premises. The court admonished the FDA for violating principles of natural justice and taking a "pedantic instead of pragmatic view," even threatening contempt action against officials.
